Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Urszula Sobol

Hematology & Oncology Arlington Heights, IL Medical Doctor

NPI 1326203365 CMS profile 1313435

880 W Central Rd, Suite 8200, Arlington Heights, IL 60005

Open in the dashboard

General payments

$14,666

645 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$393,738 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Urszula Sobol of Arlington Heights, IL is reported in the CMS Open Payments database as having received $14,666 across 645 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $393,738 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 76th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,308 134
2024 General $3,189 134
2023 General $2,553 115
2022 General $2,591 98
2021 General $691 37
2020 General $461 22
2019 General $1,873 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Urszula Sobol
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Urszula Sobol were reported at $3,308. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Urszula Sobol Hematology & Oncology median Middle half National median
2019 $1,873 $529 $121–$2,516 $163
2020 $461 $339 $82–$2,213 $114
2021 $691 $263 $49–$1,965 $132
2022 $2,591 $416 $103–$2,395 $149
2023 $2,553 $542 $125–$2,646 $160
2024 $3,189 $692 $141–$3,008 $164
2025 $3,308 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,353 71 payments
  2. Merck Sharp & Dohme Corporation $1,026 51 payments
  3. Pfizer Inc. $704 42 payments
  4. Amgen Inc. $680 22 payments
  5. Gilead Sciences, Inc. $672 26 payments
  6. EMD Serono, Inc. $648 17 payments
  7. Janssen Biotech, Inc. $591 25 payments
  8. E.R. Squibb & Sons, L.L.C. $555 31 payments
  9. Seattle Genetics, Inc. $490 16 payments
  10. Genentech USA, Inc. $487 23 payments
  11. Other $7,461 321 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,097 637 payments
  2. Education $570 8 payments
Products named General payments · program years 2019–2025
  1. KEYTRUDA $939 47 payments
  2. Lenvima $424 21 payments
  3. Trodelvy $399 13 payments
  4. KISQALI $379 22 payments
  5. OPDIVO $351 19 payments
  6. ERLEADA $288 10 payments
  7. TECENTRIQ $282 13 payments
  8. IBRANCE $279 16 payments
  9. ICLUSIG $263 10 payments
  10. SARCLISA $244 11 payments
  11. Other $12,700 594 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,131

Median for Hematology-Oncology: 604

Drug cost

$437,570

Median for Hematology-Oncology: $1,306,514

Branded share of claims

25.4%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Calquence Acalabrutinib Maleate Brand 16 $216,051
Eliquis Apixaban Brand 176 $154,874
Xarelto Rivaroxaban Brand 27 $27,765
Creon Lipase/Protease/Amylase Brand 12 $23,108
Letrozole Generic 205 $4,265
Anastrozole Generic 196 $3,253
Exemestane Generic 24 $1,690
Dexamethasone Generic 79 $736
Ondansetron Hcl Generic 14 $722
Hydroxyurea Generic 26 $641

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 129 billing codes

Paid by Medicare

$3,987,782

Of which drugs: $3,678,594

Medicare patients

715

Average age 76

Services billed

202,396

469 women, 246 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 56%
Arthritis 54%
Ischemic heart disease 33%
Diabetes 27%
Chronic kidney disease 22%
Atrial fibrillation 20%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 25 28,500 $1,271,704
Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 Office 11 12,960 $485,933
Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg Q5122 Office 24 1,056 $60,317
Injection, ferric derisomaltose, 10 mg J1437 Office 20 2,400 $37,344
Injection, denosumab, 1 mg J0897 Office 14 1,380 $28,678
Injection, aprepitant, 1 mg J0185 Office 11 3,380 $4,522
Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg J9196 Office 16 497 $3,411
Injection, fluorouracil, 500 mg J9190 Office 12 1,124 $2,577
Injection, fosaprepitant, 1 mg J1453 Office 25 17,850 $1,926
Injection, palonosetron hcl, 25 mcg J2469 Office 36 1,500 $1,043

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 68 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $134
$134 — —
XOSPATA
  • Astellas Pharma US Inc $113
$113 — —
KISQALI
  • Novartis Pharmaceuticals Corporation $112
$112 — —
Fabhalta
  • Novartis Pharmaceuticals Corporation $101
$101 — —
Lenvima
  • Eisai Inc. $100
$100 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 68 with Patron

Records

645 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record